Clinical autoantibody detection by microarray

Doreen Dillaerts; Heidi De Baere; Xavier Bossuyt

doi:10.1515/cclm-2016-0533

Article

Clinical autoantibody detection by microarray

Doreen Dillaerts , Heidi De Baere and Xavier Bossuyt

Published/Copyright: September 22, 2016

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 55 Issue 4

Abstract

Background:

AMiDot is a microdot array-based immunoassay that allows simultaneous detection of multiple autoantibodies on a single patient. We evaluated the AMiDot “Systemic Autoimmune Disease” (SAD) panel, which detects antibodies to 17 different antigens.

Methods:

AMiDot was performed on 184 samples from blood donors and on 280 randomly selected clinical samples containing antibodies to extractable nuclear antigens or to dsDNA. The results obtained by AMiDot on the clinical samples were compared to results obtained by EliA (Thermo Fisher) for anti-Ro60, anti-La, anti-RNP, anti-Scl-70, anti-CENPB, anti-Sm, and anti-Jo-1 and by Farr assay for anti-dsDNA. Discordant results were further analyzed by immunodot (D-tek).

Results:

Concordance between AMiDot and EliA was ≥87% and κ agreement ≥0.44. When compared to EliA and immunodot (in case of discordance between AMiDot and EliA), concordance improved to ≥91% and κ agreement to ≥0.77. The sensitivity of AMiDot (compared to EliA and immunodot, in case of discordance between AMiDot and EliA) was ≥93%, except for anti-Ro60 (84%). The concordance and κ agreement of AMiDot with the Farr assay (for dsDNA antibodies) was, respectively, 84% and 0.33. The sensitivity of AMiDot for dsDNA (compared to Farr assay) was 25%. The specificity was ≥97% (in blood donors as well as in clinical samples). The within-run imprecision was 9%–27% and the between-run imprecision 29%–39%.

Conclusions:

AMiDot offers an alternative to line immunodot assay. Individual antibody assays might suffer from low sensitivity.

Keywords: anti-nuclear antibodies; autoantibodies; microarray

Acknowledgments

We thank Keith Rawson for helpful discussions and Menarini for providing reagents and supporting the study.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: X.B. has received lecture fees from Menarini.
Employment or leadership: H.D. is employed by Menarini.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17–23.10.1136/annrheumdis-2013-203863Search in Google Scholar PubMed

2. Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014;2014:315179.10.1155/2014/315179Search in Google Scholar PubMed PubMed Central

3. Op De Beéck K, Vermeersch P, Verschueren P, Westhovens R, Mariën G, Blockmans D, et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012;12:137–43.10.1016/j.autrev.2012.02.013Search in Google Scholar PubMed

4. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002;8:295–301.10.1038/nm0302-295Search in Google Scholar PubMed

5. Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol 2014;133:880–2.e10.10.1016/j.jaci.2013.11.038Search in Google Scholar PubMed PubMed Central

6. Glick MR, Ryder KW, Jackson SA. Graphical comparisons of interferences in clinical chemistry instrumentation. Clin Chem 1986;32:470–5.10.1093/clinchem/32.3.470Search in Google Scholar

7. Bossuyt X, Schiettekatte G, Bogaerts A, Blanckaert N. Serum protein electrophoresis by CZE 2000 clinical capillary electrophoresis system. Clin Chem 1998;44:749–59.10.1093/clinchem/44.4.749Search in Google Scholar

8. Kallenberg CG. Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. Curr Opin Rheumatol 2016;28:8–14.10.1097/BOR.0000000000000233Search in Google Scholar PubMed

9. Bossuyt X, Louche C, Wiik A. Standardisation in clinical laboratory medicine: an ethical reflection. Ann Rheum Dis 2008;67:1061–3.10.1136/ard.2007.084228Search in Google Scholar PubMed

10. Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I, Borghi MO. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol 2014;10:35–43.10.1038/nrrheum.2013.180Search in Google Scholar PubMed

11. Autoantibody Standardization Committee. AutoAb.org. Available at: http://asc.dental.ufl.edu/.Search in Google Scholar

12. Harmonisation of Autoantibody Tests (WG-HAT). International Federation of Clinical Chemistry and Laboratory Medicine. Available at: http://www.ifcc.org/ifcc-scientific-division/sd-working-groups/harmonisation-of-autoantibody-tests-wg-hat.Search in Google Scholar

13. Shoenfeld Y, Cervera R, Haass M, Kallenberg C, Khamashta M, Meroni P, et al. EASI – The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. Ann N Y Acad Sci 2007;1109:138–44.10.1196/annals.1398.016Search in Google Scholar PubMed

Received: 2016-6-18

Accepted: 2016-7-29

Published Online: 2016-9-22

Published in Print: 2017-3-1

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/cclm-2016-0533

Keywords for this article

anti-nuclear antibodies; autoantibodies; microarray